The company Ipsen announced the receipt of the compelling clinical study results phase III CheckMate-9ER conducted to assess the efficacy of the combination of Casentino and nicolumbo in comparison with sunitinib in patients with previously treated or widespread metastatic renal cell carcinoma (RCC).
The study achieved these KPIs as progression-free survival and overall survival in patients with previously treated kidney cancer. Positive results of the study confirm the growing array of data, indicating that casentini can create a more immune-permissive microenvironment of the tumor, which may enhance the response to inhibitors of immune checkpoints, said Dr. Howard Mayer, Executive Vice President and head of research and development of the company Ipsen.
Research CheckMate -9ER is an open, randomized, international phase III investigation, which involved patients with advanced or metastatic renal cell cancer who have not previously received treatment. Patients were randomized in a 1:1 ratio to receive the combination of Casentino and nicolumbo or sunitinib. The primary endpoint is progression-free survival (VBP). Secondary endpoints include overall survival (OS) and frequency of objective response rate (ORR). During the primary effectiveness analysis was conducted comparing the combination of nicolumbo with Casentino and sunitinib all randomized patients. Detailed results of the study will be presented at one of scientific conferences.
In 2019, casentini was registered in Russia for the treatment of advanced renal cell carcinoma (RCC) in adult patients with intermediate or poor prognosis, who had not previously received systemic therapy, in adult patients following prior treatment targeted agents against growth factor vascular endothelial (VEGF). Casentini belongs to a new generation of tyrosine kinase inhibitors. It blocks the action of the important components of tumor progression (VEGFR, MET, AXL), thus preventing tumor angiogenesis, invasiveness, metastasis and drug resistance.